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Fourteen patients who developed B cell lymphomas or lymphoproliferative lesions after 
kidneY,liver, heart, or heart-lung transplantation in Pittsburgh during 1981-1983 had ac-
tive infection with Epstein·Barr virus (EBV) of the primary (six patients), reactivated (seven 
patients), or chronic (one patient) type. In transplant patients without tumors, the inci-
dence of EBV infection was 30070 (39 of 128). Only three of these patients had primary 
infections. Thus the frequency of active infection was significantly higher in patients with 
tumors, and patients with primary infections were at greater risk of developing tumors. 
Five of 13 tumors tested contained EBV nuclear antigen (EBNA) and nine of II con-
tained EBV genomes detected by DNA-DNA hybridization with BamHI K, BamHl W, 
or EcoRI B cloned probes. All EBNA-positive tumors, except one, were also positive by 
hybridization. Only one tumor was negative for both EBNA and EBV DNA. These data 
suggest that EBV plays an etiologic role in the development of these lesions. 
Epstein-Barr virus (EBV) is a human herpesvirus as-
sociated with an array of conditions that range from 
inapparent infection and infectious mononucleosis 
to lethal Iymphoproliferative syndromes, naso-
pharyngeal carcinoma, Burkitt's lymphoma, and B 
cell lymphomas in immunocompromised patients 
[1]. The precise role of the virus in carcinogenesis 
is unclear, although in Burkitt's lymphoma the im-
portance of viral transformation of infected B lym-
phocytes and chromosomal translocations has been 
emphasized [2]. It is even less clear in lymphomas 
and Iymphoproliferative lesions arising in immuno-
compromised patients, where the immunopathology 
may not be uniform and where chromosomal 
studies are largely lacking. 
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Recently, we reported on the reversibility of lym-
phomas and lymphoproliferative lesions in a series 
of 17 transplant patients after reduction of cyclospo-
rine and steroid immunosuppression [3]. In that pre-
liminary report we noted that seven of these patients 
had evidence of primary EBV infections and eight 
had evidence of reactivated infection. Six tumors had 
evidence of EBV nuclear antigen (EBNA) and seven 
had evidence of EBV DNA by nucleic acid hybrid-
ization. 
This paper examines in detail the relation between 
infection with EBV and the tumors in 14 of these 
17 patients. The three patients who were excluded 
had their original transplants in Colorado (patients 
1,2, and 3 [3]). New data provided here include (1) 
frequency of EBV infection in the general transplant 
population; (2) additional serological studies in pa-
tients with tumors; (3) correlation of laboratory evi-
dence of EBV infection and clinical illnesses accom-
panying the appearance of tumors; and (4) details 
of hybridization studies with highly specific 'and sen-
sitive probes consisting of cloned fragments of the 
EBV genome. 
Caine et al. [4] and Thiru et al. [5] first observed 
three cases of lymphoma in 34 transplant patients 
receiving cyclosporine, of whom one had evidence 
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of primary infection. Hanto et a1. [6] reported the 
results of studies on 19 renal transplant patients who 
developed lymphoproliferative disorders and lym-
phomas after transplantation. All the patients ex-
cept one were receiving azathioprine, prednisone, and 
antithymocyte globulin. Two of their patients devel-
oped primary EBV infection, in six the infection reac-
tivated, and 12 had evidence of EBV DNA in their 
tumors by hybridization studies. Bieber et a1. [7] 
reported that five of 39 heart transplant recipients 
receiving cyclosporine, prednisone, and antithymo-
cyte globulin developed lymphomas. Four tumors 
were positive for EBV DNA by cRNA-DNA filter 
hybridization, and three patients had serological evi-
dence of EBV infection. 
We report here evidence for active EBV infection 
in all of our patients with tumors and a significantly 
higher frequency of primary infection than found 
in control transplant recipients. Antibody responses 
to all EBV antigens and details of hybridization 
studies have not been reported in previous studies 
of patients with tumors. 
Materials and Methods 
Surveillance oj transplant patien ts and specimen 
collection. In 1981 cyclosporine was introduced at 
the University Health Center of Pittsburgh as the 
main immunosuppressant for transplant recipients. 
Liver, heart, and heart-lung transplantations were 
initiated, and the existing renal transplant program 
was greatly expanded. Since that time we have car-
ried out a system of prospective surveillance for her-
pesvirus infection in all transplant patients. Serum 
specimens were collected when possible before or at 
time of transplantation and at least twice monthly 
for the first three months and monthly for six to 12 
months after transplantation. Throat-wash, urine, and 
buffy coat specimens for cytomegalovirus (CMV) 
isolation were also collected at the same intervals. 
In many cases, when viral illness was suspected, ad-
ditional specimens were obtained. Complete sets of 
sera were available for all 14 patients with EBV-
related lymphomas or lymphoproliferative syn-
dromes. Five to 24 serum samples from each patient 
were titrated for antibodies to EBV antigens five to 
72 months after transplantation. Every transplant 
recipient was seen or followed up by one of us or 
by fellows of the Division of Infectious Diseases. 
Viral syndrome. A viral syndrome was defined 
t 
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as an illness with fever of at least 37.7 C that per-
sisted for four days or more and could not be at-
tributed to nonviral agents, despite careful evalua-
tion and culturing. The syndrome was assumed, 
although not proven, to be due to EBV, CMV, or 
both because of laboratory correlations. These ill-
nesses were associated with one or more of the fol-
lowing manifestations: (1) persistent pharyngitis or 
tonsillitis, (2) cervical lymphadenopathy, (3) leukope-
nia (white cell count ~4IlllFI and (4) atypicallym-
phocytosis E~lllgo atypical cells). 
Lymphoma and Iymphoprolijerative lesions. 
The definition of these two terms is based on ana-
tomic pathology, as previously reported [3]. For con-
venience we refer to the combined groups as 
"tumors." 
EBV serology and serological diagnosis. Im-
munosuppressed patients may have atypical serolog-
ical responses to EBV infection. For example, it is 
well known that antibodies to EBNA do not always 
develop in such patients after primary infection [8]. 
The sensitivity and specificity of IgM antibodies to 
viral capsid antigen (VCA) and IgG antibodies to 
early antigen (EA) are also unclear. Most authors 
have relied on changes in IgG antibody to VCA to 
diagnose EBV infection in such patients [I, 5-7]. 
For routine serological surveillance, primary EBV 
infection was diagnosed when an initially seronega-
tive individual seroconverted and developed IgG an-
tibody to VCA. The diagnosis of reactivated infec-
tion required a fourfold or greater rise in titer of this 
antibody in a previously seropositive patient. In both 
cases, unsustained antibody rises within the first 
postoperative month were excluded from consider-
ation because of possible passive transfer of anti-
bodies by transfusions. 
To evaluate the occurrence of other antibodies in 
patients with tumors, we also measured titers of IgM 
antibody to VCA, IgG antibody to EA, either D or 
R, and antibody to EBNA. IgA antibodies to VCA 
and EA were qualitatively determined. Significant 
rises in titers of IgG antibodies to VCA and EA were 
used to diagnose infection. 
The following tests were performed by indirect or 
anticomplement EBV-specific immunofluorescence 
tests. Titers of IgM and IgG antibodies to VCA were 
determined on acetone-fixed HRI-K cells by using 
fluorescein isothiocyanate (FITC)-labeled antibody 
to IgM and antibody to IgG, according to Schmitz 
and Scherer [9] and Henle and Henle (10), respec-
;.> 
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tively. In order to eliminate rheumatoid factor as a 
cause of a false-positive IgM test, we adsorbed some 
sera with heat-aggregated human gammaglobulin, 
according to Shirodaria et a1. [1t]. IgO antibody to 
EA (0 or R types) was determined according to the 
methods of Henle et al. [t2], by using Raji cells in-
duced with 5-iodo-2'-deoxyuridine. 0 antigen is de-
tectable after both acetone and methanol fixation, 
whereas R antigen is denatured by methanol fixa-
tion. Titers of antibody to EBNA were determined 
on Raji cells by using the anticomplement im-
munofluorescence test of Reedman and Klein [13], 
with human C3 and FITC-Iabeled antibody to hu-
man C3. For the determination of IgA antibodies 
to VCA and IgA antibodies to EA, specific antibody 
to human IgA was used. In all these tests, positive 
and negative human sera against the appropriate 
EBV antigens, as well as heat-inactivated (56 C for 
30 min) C3, and negative human lymphoblastoid 
(RAMOS) or leukemic myeloblastoid (K-562) cell 
lines were used as EBV specificity controls. Tests on 
selected samples for IgO antibody to VCA, IgM an-
tibody to VCA, and [gO antibody to EA were con-
firmed in the laboratory of Dr. W. Henle (Joseph 
Stokes, Jr. Research Institute, Children's Hospital, 
University of Pennsylvania, Philadelphia). 
Testsjor heterophil antibody. Selected sera from 
all patients with tumors were tested by using the Syl-
vana slide-test kit (differential slide test; GIBCO, 
Grand Island, NY). Briefly, two 20-fll aliquots of se-
rum were adsorbed with either beef erythrocyte 
stroma (10070) or guinea pig kidney tissue (10070) be-
fore addition of citrated horse red blood cells. 
CMV injection. As in previous studies [14, 15], 
CMV infection was diagnosed by recovery of CMV 
from throat, urine, or buffy coat specimens on hu-
man fibroblast monolayers, by conversion or eleva-
Ho el al. 
tion in titers of antibodies to CMV by anti-
complement immunofluorescence (14), or by both. 
Infections were classified as either primary or reac-
tivated depending upon whether the patient was 
seronegative or seropositive before transplantation. 
CMV serological and virological studies were per-
formed on all patients. 
Tests jor EBNA in tumor tissue. The presence 
of EBNA in lesions was detected by anticomplement 
immunofluorescence by using the method of Reed-
man and Klein [13). Cryostat sections or fresh-
impression smears of tissue were fixed with acetone. 
Four sera that were positive for antibody to EBNA, 
of which one was free of antibody to CMV and one 
was free of antibody to herpes simplex virus, and 
two sera that were negative for antibody to EBNA 
were used as primary reagents. 
DNA hybridization studies. Frozen ( - 70 C) tu-
mor lissue specimens were examined for their EBV 
genome content by Southern blot hybridization anal-
ysis. One specimen was studied by Joseph Pagano 
(University of North Carolina, Chapel Hill, NC) by 
using a cloned probe consisting of a BamHI W frag-
ment of EBV DNA. Two specimens were studied by 
Drs. M. L. Cleary and J. Sklar (Stanford Univer-
sity, Stanford, Calif) by using a dot blot method with 
an EcoRl B probe. 
All other tests were performed in the laboratory 
of G. M. at Yale University by using a plasmid con-
taining either the BamHI K or EcoRI B fragment 
of the EBV genome as described by Andiman et al. 
[16). Briefly, I lAg of tissue DNA was digested at 37 C 
for 2-3 hr with a sixfold excess of the restriction en-
donuclease BamHI. DNA samples were heated to 
65 C for 5 min, placed on ice for 10 min, and then 
electrophoresed through horizontal 0.5070 agarose gel 
for 18 hr at 40 V. The DNA was transferred to 
Type of transplant 
Characteristic 
Pretransplant IgG 
antibodies to VCA 
"iegative· 
PoSItive + 
Total ("'0) 
Duration of follow-up+ 
Renal 
13 
5>34 
6,)7 (16) 
5.9 ± 0.2 
Liver 
0/0 
14/41 
14/41 (34) 
3.7 ± 004 
• ~oK with serological evidence of primary infection, total no. in category. 
t ~oK with serological evidence of reactivated infection/total no. in category. 
! In months. mean :t SE. 
Heart and 
heart-lung 
17.48 
1950(J8) 
10.5 ± 1.0 
Total 
3/5 
36'123 
39!l28 (30) 
7.0 ± 0.5 
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Table 2. Lymphomas and Iymphoproliferative lesions 
(LPL) in transplant patients in Pittsburgh (December 
1979-June 1983). 
No. with 
No. of lymphoma and 
Type of transplant transplants LPL (070) 
Renal 315 5 (1.6) 
Liver 129 3 (2.3) 
Heart 48 3 (6.3) 
Heart and Lung 6 2 (33.3) 
Total 498 13 (2.6) 
nitrocellulose by blotting overnight with 20 x SSC 
(SSC: 3 M NaCI and 0.3 M sodium citrate) accord-
ing to the procedure of Southern [17]. Plasmids con-
taining the respective fragments were labeled with 
up by nick translation. Southern blots were hybrid-
ized with labeled probes at 65 C for 18-64 hr in plas-
tic bags in a shaking water bath. Blots were exposed 
to Kodak XAR5 or BBS film (Eastman Kodak, 
Rochester, NY) with intensifying screens for various 
lengths of time. Every experiment contained, as a 
positive control, a titration of the plasmid pBR322 
containing the EBV BamHI K fragment or the plas-
mid pACYC184 with the EBV EcoRI B fragment. 
Probes were prepared from these plasmids. Titrations 
of pBR-BamHI K from 100 to 1 pg represent the 
signal equivalent to 10, 1, and 0.1 copies per cell in 
a sample of 106 cells. Another positive control con-
sisted of 500 ng and 50 ng (the equivalent of 105 and 
104 cells) of BamHI-digested cellular DNA from a 
cell line (FF 467) known to contain 40 EBV genome 
copies per cell. The negative control was human 
placental DNA. 
Statistics. To compare differences in proportions 
between two groups, we used the X2 test with Yates's 
correction. 
Results 
EBV injection in transplant patients. To illus-
trate the background frequency of EBV infections 
in our transplant groups, we present results of titra-
tions of IgG antibody to VCA from 128 renal, liver. 
heart, and heart-lung recipients without lymphomas 
or Iymphoproliferative disorders (table 1). Sera were 
collected as described in Materials and Methods. A 
pretransplant and at least one posttransplant serum 
sample, covering a period ranging from J.5 to 32 
months, were titrated from each patient. The mean 
duration of follow-up was seven months. 
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The mean frequency of infection in these 128 pa-
tients was 30OJo. Only five patients were seronega-
tive before transplantation and were susceptible to 
primary infection. The frequency of primary infec-
tions among seronegative subjects was 60OJo (3 of 5), 
and 29% (36 of 123) of those who had experienced 
a primary infection in the past had a reactivated in-
fection. 
Lymphomas and Iymphoproliferative lesions in 
Pittsburgh. To estimate the frequency of these dis-
eases in the four major transplant groups as of June 
1983, we calculated the number of patients with 
tumors and the total number of transplantations (ta-
ble 2). Data on the renal transplant patients go back 
to December 1979. The other three types of trans-
plants were begun in 1981, and such organ recipients 
were given cyclosporine and prednisone. There were 
82 renal transplant recipients who were maintained 
on a regimen of azathioprine and prednisone until 
1981. After that time they too were treated exclusively 
with cyclosporine and prednisone. 
One (patient 10) of the 14 patients was not in-
cluded in the table. She received a liver transplant 
in Colorado in 1977 but was followed up by T. E. S. 
in Pittsburgh from 1981 to September 1983, at which 
time her tumor was discovered. She died shortly af-
ter retransplantation surgery. 
It is apparent that the heart and the heart-lung 
groups had a significantly higher frequency of 
tumors than did the other groups (P< .01). The same 
conclusion was reached in a summary of 5,550 trans-
plant recipients receiving cyclosporine [18]. 
Development oj antibodies to EBVantigens in pa-
tients with tumors. The antibody responses to EBV 
antigens of the 14 tumor patients before and after 
transplantation are summarized in tables 3 and 4. 
All 14 patients hdd serological evidence of active 
EBV infection. Thirteen patients had rises in their 
titers of antibody to VCA or EA, a finding.iOOicat-
ing primary or reactivated infection (table 3). One 
renal transplant patient (patient 14), a 52-year-old 
man with polycystic kidneys, did not show a rise in 
any serological marker but had persistently elevated 
IgG antibodies to EA (R) for 16 months after his 
transplant. He developed a diffuse, noncleaved large-
cell lymphoma in the left side of the neck three 
months after transplantation. This lymphoma was 
negative for EBNA and negative for EBV DNA by 
hybridization st udies. 
Six patients (patients 1-6) developed primary in-
fections. These were documented by the absence of 
-"" -to _ 
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Table 3. Serological changes during primary and reactivated EBV infections in patients with lymphoma. 
Significant changes in 
IgO IgM IgG IgA No. positive for 
Type of infection (n) anti-VCA anti-VCA anti-EA anti-yeA heterophil agglutinin (010) 
Primary (6) 6 (100) 3 (SO) 5 (83) 3 (SO) 0(0) 
Reactivated (7) 4 (57) 3 (43) 7 (100) 5 (71) I (14) 
NOTE. Primary infections are infections in patients whose pretransplant serology for EBV was negative. Reactivation occurred 
in seropositive patients. Results are no. of patients (010). 
IgO antibodies to VeA before transplantation and 
a serological conversion one to five months after 
transplantation. Five patients had concomitant con-
versions of antibodies to EA (R) from negative titers 
to titers between 1:10 and 1 :40. One (patient 2) did 
not develop antibodies to EA. Only three patients 
(patients 4, 5, and 6) developed positive titers of IgM 
antibodies to veA of 1 :5. 
Seven patients who had 19O antibodies to VeA 
before transplantation had evidence of reactivated 
infection. All but one (patient 10) of these EBV reac-
tivations occurred between one and seven months 
after transplantation. Four (patients 9-12) developed 
a fourfold or greater rise in titer of IgO antibody 
to VeA. All seven showed significant rises in IgO 
antibody to EA (R). One (patient 12) had a pretrans-
plant titer of 19O antibody to EA (R) of 1:10 that, 
at about the time of elevation of titers of IgO anti-
body to VeA, shifted to a titer of IgO antibody to 
EA (0) of 1 :20. This was the only patient in whom 
a shift from antibody to R to antibody to 0 was ob-
served. Three patients had IgM antibody to veA 
(patients 10, 12, and 13). Because rheumatoid fac-
tor may give a false-positive IgM test [19, 20), sera 
from these three patients were ret it rated after adsorp-
tion with aggregated gammaglobulin. The titers re-
mained unchanged, a result suggesting that 19M an-
tibodies to VeA may truly be present in some 
reactivated EBV infections. 
Table 3 also shows results of heterophil aggluti-
nin tests that were performed on sera selected from 
all 14 patients about the time of significant serolgi-
cal changes. The test was positive in only one pa-
tient (patient 9), who had a reactivated infection. 
Heterophil antibody was notably absent in all pri-
mary infections. 
EBV-specific IgA antibodies are a highly charac-
teristic feature of nasopharyngeal carcinoma [21, 221 
and can be found in 38070-86070 of patients with EBV 
mononucleosis [21, 231. IgA antibodies to veA and 
IgA antibodies to EA were qualitatively determined 
in all serum samples. No clear-cut pattern was de-
tected. 
Antibodies to EBNA did not develop in four of 
the six patients who had primary infections during 
the two to 19 months of follow-up (data not shown). 
Two patients (patients I and 5) developed a low titer 
(1 :5) that became negative again in one (patient 5). 
This differs from the usual situation in primary in-
fection, in which antibody to EBNAroutinely de-
velops during convalescence [24]. All seven patients 
with reactivated infections had detectable though low 
titers of antibody to EBNA before transplantation. 
In two (patients 9 and 13), antibody to EBNA be-
came undetectable during reactivated infection. The 
failure of immunosuppressed patients to develop an-
tibody to EBNA is well described [8]. 
In summary, antibody responses in EBV infections 
in these patients with Iymphoproliferative disorders 
were different from those seen in normal patients. 
In primary infections all patients seroconverted their 
IgO antibodies to VeA, and no additional cases were 
diagnosed on the basis of antibody to EA. Unlike 
primary infection in normal subjects, not all patients 
developed IgM antibodies to veA early or antibod-
ies to EBNA late in their course [24, 251, and no pa-
tient with primary infection developed a heterophil 
agglutination titer. It is possible, of course, that in 
some cases a transient IgM titer was missed [26]. 
Reactivated infections were less easy to diagnose 
and interpret. They were generally diagnosed by sig-
nificant rises in titers of IgG antibody to VCA or 
EA in patients who were seropositive for IgO anti-
body to VCA before transplantation. A majority 
(four of seven patients) had significant rises in titers 
of IgG antibody to VC A, and all seven patients had 
significant rises in titers of antibody to EA. Changes 
in antibody to EA (R) in transplant patients indica-
tive of reactivated infection were shown by Chees-
man et al. [27). In nonimmunosuppressed patients 
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with persistent symptomatology, elevated titers of 
antibody to EA (D or R) have been (;orrelated with 
active, persistent EBV infection [28, 29]. 
IgM antibody to VCA was not diagnostic of pri-
mary infection as it occurred in three reactivated in-
fections. This has been described in normal subjects 
[301. The appearance of IgM antibody to CMV has 
also been described in reactivated CMV infections 
in immunosuppressed heart transplant recipients 
[31]. 
Clinical association with EBV injection. Table 
4 also lists data concerning the nature of the EBV 
infection and tumors in the 14 patients. Five of six 
patients with primary EBV infections developed a 
symptomatic "viral syndrome" two to five months 
after transplantation. The one patient with a primary 
EBV infection who did not have a viral syndrome 
(patient 1) was first noted to have gastrointestinal 
bleeding. A gastric ulcer was found that on biopsy 
showed a diffuse large-cell lymphoma. 
Viral syndromes occurred less often in the patients 
with reactivated EBV infections (three of seven) but 
were similar to those seen in primary EBV infections. 
It was not always possible to ascribe the viral syn-
drome to EBV infection, as eight of 14 patients also 
had primary or reactivated CMV infections (table 
4). However, six patients did not have any evidence 
of CMV infection by culture or serology. Three (pa-
tients 2, 6, and 11) had viral syndromes that could 
only be accounted for by EBV. 
These viral syndromes occurred either at or up to 
a few months before the diagnosis of a tumor. In 
13 of 14 patients, the tumors developed within eight 
months of transplantation. The presence or absence 
of a viral syndrome did not predict the histological, 
biologic, and virological properties of the tumor. 
Development ojtumors and evidence oj EBV ac-
tivity. Table 4 lists the histological and immuno-
pathological diagnoses of the tumors in these 14 pa-
tients. Except for two, who had B lymphocyte hyper-
plasia, all patients had malignant B cell lymphomas. 
As previously reported (3), the pathology and c10-
nality of the tumor did not predict the clinical course, 
the outcome, or whether tumor progression was re-
versible. 
No fresh tissue was available from patient 3. 
Tumors from the remaining 13 patients were exam-
ined for EBNA or EBV DNA or both by blot hy-
bridization. Tissues from 11 patients were examined 
by both techniques. Ten (77 a7o) of 13 were positive 
by one method or the other. 
Ho et 01. 
A8CDEFGHI J KLM 
Figure l. Southern blot analysis of tumor tissue from 
organ transplant recipients with the EBV probe EcoRI B. 
Lane A contains the equivalent of 330 copies per cell of 
probe DNA in a sample of 10" cells. Lane D contains 
DNA from a lymphoid line containing 40 genome copies 
per cell; the DNA from 10' cells was loaded in this lane. 
Lane E contains DNA from an EBV-negative cell line. 
Lanes F and G contain Illg and 500 ng, respectively, of 
DNA from the lung biopsy of a heart transplant recipient 
(patient 13); lanes H and I contain I jAg and 500 ng, 
respectively, of DNA from a lymph node of a heart-lung 
transplant recipient (patient 6); lanes J and K contain 1 
Ilg and 500 ng of DNA from one tonsil, and lanes Land 
M contain Illg and 500 ng of DNA from the other tonsil 
of patient 5, a heart-lung transplant recipient. EBV DNA 
was found in tissues from patients 13 and 5 but not 6. 
Lanes G, K, and M each contain the DNA equivalents 
of 10' cells. The signals corresponding to these three 
samples represent the equivalent of rv40 copies per cell. 
Note that all samples contain a group of BamHI frag-
ments expected to be present in EcoRI B probe. 
Results of seven blot hybridizations with either the 
£CoRI B or BamHI K fragment as probes are pre-
sented in figures 1 and 2. To summarize, the sensi-
tivity of the EcoRI B probe is about four copies per 
cell (figure I). About 30 copies per cell were detected 
in the lung of patient 13, and 30-40 copies per cell 
were detected in the two tonsil specimens from pa-
tient 5. None were detected in the lymph node of 
patient 6. Note that all positive samples contained 
a group of BamHI fragments that were expected to 
be present in EcoRI B and separated by Southern 
blot analysis, \vhich makes the findings even more 
convincing. The sensitivity of the BamHI K probe 
was about one copy per cell (figure 2). The prostate 
specimen from patient 7 contained >10 copies per 
cell, the intestinal tumor of patient II had "-'10 copies 
per cell, the mesenteric lymph node of patient 9 had 
about one copy per cell. and the intestinal tumor of 
patient 8 had >10 copies per cell. The weak positive 
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Figure 2. Southern blot analysis with the EBV probe 
BamHI K, Titration of the probe is found in lanes a-c. 
Lane a contains 100 pg of the probe. Lane b contains 10 
pg of BamHI K. the equivalent of one genome copy per 
cell in 106 cells. Lane c contains 1 pg, Lane d contains 
DNA from a lymphoid line containing 40 copies per cell; 
the DNA from 1()5 cells was loaded in this lane, Thus. 
the signal is equivalent to four copies per cell in a sample 
of 1 ()6 cells. Lane e is a negative control. Lanes f -i contain 
5 fJg of DNA from each of four patients (7, II, 9, 8); 
this is rv 106 cell equivalents of DNA per lane. Thus, 
samples f, g. and i have 10 copies per cell, and sample 
h has four copies per cell. Lanes j and k contain DNA 
from an unrelated patient. The BamHI K fragment is 
known to vary in size. 
result by blot analysis may possibly be related to the 
fact that patient 9 was diagnosed as having a lym-
phoproliferative syndrome. 
The lymph node of patient 6 was also tested by 
M. Cleary and J. Sklar at Stanford by dot hybrid-
ization with an £CoRI B probe and was found, in 
contrast to the above results, to be positive. This may 
be due to a difference in the sensitivity of the test 
in two laboratories, or the dot blot may give non-
specific hybridization, More likely, it represents the 
presence of more genome-positive cells at one site 
than at another. 
The hybridization test seemed to be more sensi-
tive than the test for EBNA. This would be expected, 
based on the size of the specimen that could be ex-
amined by the two methods. Also, EBNA is quite 
labile. The tumor of patient 10 was positive for 
EBNA but negative by hybridization. This patient's 
tumor cells were cultured and passed in vitro. They 
were uniformly positive for EBNA and their karyo-
type was normal (R, W. A., unpublished obser-
vation), 
There was only one patient whose tumor was nega-
tive for both EBV markers - patient 14. This was the 
only patient in the series who did not have serologi-
cal evidence of a primary or reactivated EBV infec-
tion but had persistent antibody to EA, which we 
interpreted as indicating active chronic infection. The 
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clinical course of this patient was not different from 
the others. 
Discussion 
The frequency of EBV infection in our transplant 
populations varied from 16070 to 38% (mean, 30%) . 
Renal transplant patients had a lower rate of EBV 
infection than did the other transplant groups, but 
this observation requires further substantiation. 
In contrast, 13 of our 14 patients with tumors had 
evidence of primary or reactivated EBV infection. 
Patient 14 had evidence compatible with chronic in-
fection. Excluding this patient, the rate of infection 
was 93%. This was significantly higher than the rate 
of primary or reactivated EBV infection in the 
general transplant population (P < .00(5). Not all 
reactivated EBV infections in patients with tumors 
were detected by the test for IgG antibody to VCA 
alone. By using rises in titers of IgG antibody to VCA 
as the sole criterion, 10 of 14 tumor patients had evi-
dence of infection (table 3). This rate was still sig-
nificantly higher than the rate of infection for the 
whole transplant group (P < .005). Another objec-
tion may be that in the general popUlation, inade-
quate length of follow-up may have precluded de-
tection of late infections. To address this point, we 
first note that EBV infection in most tumor patients 
was detected by 4.5 months after transplantation (10 
of 13; table 4). Eliminating all patients with <4.5 
months of follow-up from the cohort of table 1, we 
still have 97 patients and an infection rate of 39%, 
This is still lower than the infection rate in tumor 
patients with the test for IgG antibody to VCA alone 
(P < .05). Thus, there was a significant association 
between the development of tumors and the pres-
ence of EBV infection. 
Patients with primary EBV infections seemed to 
be at greatest risk. Six (43070) of 14 patients who de-
veloped tumors had primary EBV infections. This 
is significantly different from the proportion of pri-
mary EBV infections in a population of patients 
without tumors (table 1; 3 [8%] of 39, P < .0\), This 
point is not evident from previous reports [4, 7). 
The rates of EBV infection in our transplant popu-
lations were significantly lower than were the rates 
of CMV infection: they were, respectively. 77070. 66070, 
and 96070 in renal, liver, and heart and heart-lung 
recipients [32]. Cheeseman et al. [27] found that all 
the renal transplant patients in their series were ini-
l 
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tially seropositive, and only those patients who re-
ceived anti thymocyte globulin reactivated. Marker 
et al. [33] reported that 30 (34070) of 88 transplant 
patients who also received antithymocyte globulin 
had serological changes indicative of EBV infection. 
Our own previous work [34] showed that 32070 of 
renal patients on azathioprine and prednisone de-
veloped EBV infection, as detected serologically. It 
is possible that reported reactivation rates are falsely 
low since, as shown in this paper, some cases can 
only be detected by the demonstration of a rise in 
titers of antibody to EA. 
Morbidity due to EBV infection after organ trans-
plantation has not received as much attention as 
morbidity due to CMV infection. EBV mononucle-
osis and malignant lymphoproliferative syndromes 
have been reported [33, 35], and pneumonitis or pul-
monary infiltrates due to EBV have been suspected 
(27]. It is quite clear from our data that a "viral syn-
drome" may accompany EBV infection, particularly 
if the infection is primary. CMV may have played 
a role in some of these viral illnesses, but we have 
patients in whom no CMV infection could be 
documented. 
It is unclear whether the development of lympho-
mas was enhanced by the use of cyclosporine, as op-
posed to other immunosuppressants. None of the 
renal tranplant recipients who developed lympho-
mas were receviving azathioprine, but the total num-
ber of patients taking azathioprine was too small for 
adequate analysis. Experience from \-tinnesota, how-
ever, shows that such patients are also at risk (6]. 
There is no experience in Pittsburgh with liver or 
heart transplant patients using other immunosup-
pressants. The heart and heart-lung transplant pa-
tients seem to be at greatest risk (this paper, [l8]). 
This may reflect the use of supplemental antithymo-
cyte globulin therapy in four of the five heart and 
heart-lung transplant patients with tumors. However, 
we documented high rates of EBV and other her-
pesvirus infections in the heart transplant patients 
at our institution before the introduction of an-
tithymocyte gl,)bulin therapy [36]. Thus, other fac-
tors, as yet undefined, related to the type of trans-
plant may be important. 
Bieber el a!. (7] reported that IO (5!ro) of 200 heart 
transplant recipients receiving azathioprine, predni-
sone, and ant it hymocyte globulin developed lympho-
mas, whereas five (13 iro) of 39 developed lympho-
mas when cyclosporine was substituted for 
azathioprine. It is likely that the occurrence of such 
... 
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tumors may be decreased by adjustment of cyc!ospo-
rine doses guided by serum levels (18]. 
Evidence for EBV infection in patients with 
tumors was matched by evidence for EBV viral mark-
ers in their tumors. Ten (91070) of 11 specimens ex-
amined for both EBNA and the presence of EBV 
DNA by blot hybridization were positive for one or 
both markers. Nine were positive by hybridization 
alone. These findings should be viewed against the 
background that positive EBV hybridizations were 
not found in 48 lymphomas and leukemias in non-
transplant patients (16]. It is possible that increased 
sensitivity of the hybridization techniques, which are 
now limited to rv 1()4 genomes or more would have 
allowed us to detect EBV in all of our tumors. 
The precise role that EBV infection plays in the 
genesis of these tumors is unknown. Hanto et al. [6] 
postulate a hierarchy of disorders: a nonmalignant 
lymphoproliferative disorder, polyclonal B cell 
hyperplasia, polyclonal B cell lymphoma, and finally, 
monoclonal B cell lymphoma. Patients were also 
divided into a younger or older group and a group 
with early or late onset. They suggest that the tu-
mor may progress from polyclonality to monoclo-
nality, although more direct evidence for such 
progression is not available. We did not see a differ-
ence in the clinical course according to age, time of 
onset, or clonality. In fact it was difficult to distin-
guish the two patients with B cell hyperplasia from 
the 12 with lymphomas, except by tissue examina-
tion. Possibly we are primarily describing what they 
would consider to be early tumors. 
In addition to immortalization of B lymphocytes, 
oncogenesis by EBV in Burkitt's lymphoma requires 
chromosomal transformation (2). Hanto et al. (6] 
describe the karyotypes of six lymphomas. A num-
ber of these were abnormal, but the translocation 
from chromosome eight to 14, commonly seen in 
Burkitt's lymphoma, was not found. We have exam-
ined the chromosomes from cells cultured from a 
diffuse large-cell lymphoma of patient 10. All of 
these cells were diploid, and no aberrations were ob-
served (R. W. A. and S. Pan, unpublished data). Fur-
ther chromosomal studies are clearly needed to de-
fine the complex biology of these tumors. 
Finally, although reactivated EBV infection has 
already been clearly correlated with tumors, we have 
ascertained that patients with primar\" EBV infec-
tions are at much greater risk of developing lympho-
mas or the lymphproliferative syndrome. The ques-
tion arises as to how these tumors may be prevented. 
EBV and POSllransp(antation Lymphomas 
Patients at risk for primary infection are easily iden-
tified by measuring pretransplant sera for antibod-
ies to EBV. Should a vaccine against EBV be devel-
oped, seronegative transplant recipients would be 
candidates for immunization. The possible benefits 
of specific immunoglobulins, interferon, or antiviral 
agents administered prophylactically should also be 
considered. We have not observed a therapeutic ef-
fect with acyclovir in these conditions, and we reem-
phasize the importance of decreasing immunosup-
pression [3]. We suggest that the accumulation of 
more data of the type we have presented on EBV in-
fections and lymphomas is necessary to ascertain the 
extent of this problem, particularly after routine 
monitoring of serum cyclosporine levels has become 
common practice. 
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